oneplacenews
Source: Ars Technica
Summary
The FDA has approved a second species of carcass-eating fly for use in maggot therapy aimed at treating wounds. This decision expands the options for doctors to use live larvae in healing chronic wounds more effectively.
Why It Matters
The approval of this new fly species signifies advancements in wound care treatment, particularly for patients with chronic wounds who may not respond to conventional therapies. Maggot therapy harnesses the natural healing properties of larvae, promoting tissue regeneration and reducing infection. By broadening the biological tools available to healthcare providers, it could improve patient outcomes and reduce healthcare costs.
